drugset
drugset / Trial / NCT00822458

GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment

NCT00822458 ↗

Phase 1 Completed 34 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of GDC-0449 in treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment. GDC-0449 may be effective in treating young patients with medulloblastoma.

Timeline

Start
2009-01
Primary completion
2013-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Vismodegib Small molecule — Oral

Indications

childhood medulloblastoma